References
- Terrin B N., McWilliams N B., Maurer H M. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr 1984; 104: 138–140
- Marty M. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic‐induced emesis. Eur J Cancer 1992; 28A(1)S12–S16
- Pinkerton C R., Williams D, Wooten C, Meller S T., McElwain T J. 5‐HT3 antagonist ondansetron: an effective out‐patient anti‐emetic in cancer treatment. Arch Dis Child 1990; 65: 822–825
- Lemerle J, Amaral D, Southal D P., Upward J, Murdoch R D. Efficacy and safety of granisetron in the prevention of chemotherapy‐induced emesis in paediatric patients. Eur J Cancer 1991; 27: 1081–1083
- Leibundgut U, Lancranjan I. First results with ICS 205–930 (5‐HT3 receptor antagonist) in prevention of chemotherapy‐induced emesis. Lancet 1987; 1(8543)1198
- Hachimi S, Schepper J, Maurus R, Otten J. Prevention of emesis by ICS 205–930 in children receiving cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 854–856
- Gershanovich M, Kolygin B, Pirgach N. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann Oncol 1993; 41(S3)35–37
- Cefalo G, Rottoli L, Armiraglio A, Pagan M G. Tropisetron (ICS 205–930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide‐based treatments. Am J Pediatr Hematol Oncol 1994; 16(3)242–245
- Stevens R F. The role of ondansetron in paediatric patients: a review of three studies. Eur J Cancer 1991; 27(1)S20–S22